Finance

Lists
BHVN:NYSE
Biohaven Ltd
$13.89
+15.61%
(+1.88) 1D
$13.84
-0.36% (-0.050)
After hours
Closed: Sep 17, 4:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BHVN...
Open
$12.18
High
$14.32
Low
$12.05
Mkt. cap
2.10B
Avg. vol.
3.02M
Volume
5.82M
52-wk high
$18.57
52-wk low
$7.48
EPS
-$4.64
Beta
3.16
Shares outstanding
151.04M
No. of employees
274
Open
$12.18
High
$14.32
Low
$12.05
Mkt. cap
2.10B
Avg. vol.
3.02M
Volume
5.82M
52-wk high
$18.57
52-wk low
$7.48
EPS
-$4.64
Beta
3.16
Shares outstanding
151.04M
No. of employees
274
News stories
From web sources and news partners
About Biohaven Ltd
CEO-
Employees274
Founded2022
HeadquartersNew Haven, Connecticut, United States
SectorBiotechnology
Websitebiohaven.com
Analyst ratings
Based on 11 analysts giving stock ratings to BHVN in the past 3 months
Buy
Buy
7
Hold
3
Sell
1
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for BHVN in the last 3 months.
Highest
Current $13.89
$30.00 (+115.98%)
Average
$20.00 (+43.99%)
Lowest
$10.00 (-28.01%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tessa Romero
J.P. Morgan
Buy
Maintained
-
-
09/13/2026
Douglas Tsao
H.C. Wainwright
Hold
Maintained
$10.00
-28%
09/10/2026
Christopher Raymond
Raymond James
Buy
Maintained
-
-
09/10/2026
Myles Minter
William Blair
Hold
Reiterated
-
-
09/09/2026
Leonid Timashev
RBC Capital
Hold
Downgraded
$19.00
+36.8%
09/08/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
$21.00
+51.2%
08/28/2026
Dina Ramadane
Bank of America Securities
Sell
Reiterated
$11.00
-20.8%
08/26/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$30.00
+116%
08/17/2026
Terence Flynn
Morgan Stanley
Buy
Maintained
$19.00
+36.8%
08/12/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$30.00
+116%
08/11/2026
David Hoang
Deutsche Bank
Buy
Reiterated
$20.00
+44%
06/26/2026
Corinne Johnson
Goldman Sachs
Buy
Maintained
$25.00
+80%
05/28/2026
Ashwani Verma
UBS
Hold
Reiterated
$11.00
-20.8%
05/28/2026
Unknown Analyst
Bernstein
Hold
Maintained
$9.00
-35.2%
05/13/2026
Samantha Semenkow
Citi
Buy
Maintained
$17.00
+22.4%
04/02/2026
Last report
Aug 10, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.78 / -$0.61
-27.61%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
141.17M
84.93M
103.83M
100.81M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
28.21M
20.79M
26.60M
24.08M
Operating expense
169.38M
105.72M
130.43M
124.90M
Total operating expenses
169.38M
105.72M
130.43M
124.90M
Operating income
-169.38M
-105.72M
-130.43M
-124.90M
Other non operating income
-7.25M
-5.29M
-3.08M
-14.70M
EBT including unusual items
-173.22M
-145.20M
-130.26M
-136.92M
EBT excluding unusual items
-176.63M
-111.01M
-133.51M
-139.60M
Income tax expense
221.00K
351.00K
272.00K
391.00K
Effective tax rate
-0.13%
-0.24%
-0.21%
-0.29%
Other operating expenses
-
-
-
-
Net income
-173.44M
-145.56M
-130.53M
-137.31M
Net profit margin
-
-
-
-
Earnings per share
-1.47
-0.90
-0.69
-0.78
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-166.26M
-103.15M
-128.06M
-122.64M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps